Cargando…
Euglycemic DKA (euDKA) as a presentation of COVID‐19
COVID‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients.
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753533/ https://www.ncbi.nlm.nih.gov/pubmed/33362928 http://dx.doi.org/10.1002/ccr3.3540 |